United Therapeutics EVP sells 8,300 shares
United Therapeutics’ EVP & General Counsel exercised 8,300 options and sold the resulting shares under a pre-arranged Rule 10b5-1 plan.
Rhea-AI Filing Summary
UNITED THERAPEUTICS Corp (UTHR) executive Paul A. Mahon, EVP & General Counsel, reported exercising stock options for 8,300 shares of common stock on September 3, 2026 at an exercise price of $146.03 per share and selling the resulting 8,300 shares in a series of trades on the same date. The filing states these option exercises and share sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan entered into on August 11, 2025. Following the exercise, Mahon continues to hold 55,840 stock options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 8,300 shares ($2.79M approx. pre-tax spread)
Exercise and Sale
13 txns
Insider
MAHON PAUL A
Role
EVP & GENERAL COUNSEL
Sold
8,300 shs ($4.00M)
Approx. gross sale proceeds
$4.00M
Approx. exercise cost
$1.21M
Approx. pre-tax spread
$2.79M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1 | 8,300 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 8,300 | $146.03 | $1.21M |
| Sale | Common Stock F1, F2 | 1,545 | $478.9344 | $740K |
| Sale | Common Stock F1, F3 | 936 | $479.6575 | $449K |
| Sale | Common Stock F1, F4 | 2,360 | $480.8613 | $1.13M |
| Sale | Common Stock F1, F5 | 1,048 | $481.917 | $505K |
| Sale | Common Stock F1, F6 | 160 | $482.6625 | $77K |
| Sale | Common Stock F1, F7 | 200 | $483.8494 | $97K |
| Sale | Common Stock F1, F8 | 954 | $485.1228 | $463K |
| Sale | Common Stock F1, F9 | 598 | $486.4682 | $291K |
| Sale | Common Stock F1, F10 | 169 | $487.3622 | $82K |
| Sale | Common Stock F1 | 10 | $488.32 | $5K |
| Sale | Common Stock F1 | 320 | $490.885 | $157K |
Holdings After Transaction:
Stock Option — 55,840 contracts (Direct);
Common Stock — 45,172 shares (Direct)
Footnotes (10)
- F1. This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
- F10. This transaction was executed in multiple trades at prices ranging from $487.06 to $487.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2. This transaction was executed in multiple trades at prices ranging from $478.23 to $479.225. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. This transaction was executed in multiple trades at prices ranging from $479.24 to $480.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $480.26 to $481.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $481.34 to $482.33. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $482.38 to $482.875. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $483.42 to $484.115. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $484.81 to $485.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $486.025 to $487.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Options exercised: 8,300 shares
Exercise price: $146.03 per share
Shares sold: 8,300 shares
+4 more
7 metrics
Options exercised
8,300 shares
Stock options for United Therapeutics common stock exercised on September 3, 2026
Exercise price
$146.03 per share
Exercise price of stock options exercised for 8,300 shares
Shares sold
8,300 shares
Total United Therapeutics common shares sold in multiple trades on September 3, 2026
Example sale price
$478.93 per share
One reported weighted average sale price for 1,545 shares of common stock
Highest reported weighted average sale price
$490.89 per share
Weighted average price for a 320-share sale of common stock
Remaining stock options
55,840 options
Stock options held directly by the reporting person following the exercise
Option expiration date
March 15, 2027
Expiration date of the stock options from which 8,300 shares were exercised
Key Terms
Rule 10b5-1 plan, stock options, weighted average price, multiple trades
4 terms
Rule 10b5-1 plan regulatory
"exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
stock options financial
"This is an exercise of stock options and sale of the resulting shares"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
weighted average price financial
"The price reported above reflects the weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
multiple trades financial
"This transaction was executed in multiple trades at prices ranging from"
FAQ
What insider transactions did UTHR’s EVP & General Counsel report on this Form 4?
He reported exercising 8,300 stock options for United Therapeutics common stock and then selling 8,300 shares of common stock in multiple trades on September 3, 2026, all as one exercise-and-sell sequence.
At what price were the UTHR stock options exercised in this filing?
The options were exercised at an exercise price of $146.03 per share for 8,300 shares of United Therapeutics common stock. These options were originally granted with an exercise date of March 15, 2020 and an expiration date of March 15, 2027.
Were the UTHR insider transactions made under a Rule 10b5-1 plan?
Yes. A footnote states that the option exercise and resulting share sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan entered into by the reporting person on August 11, 2025, and the filing’s Rule 10b5-1 checkbox is affirmed.
How many stock options does the UTHR executive hold after these transactions?
After exercising 8,300 stock options, the reporting person directly holds 55,840 stock options for United Therapeutics common stock, as shown in the post-transaction derivative holdings for the option position reported.
AI-generated analysis. How Rhea-AI works. Not financial advice.
